Webinar – Reduce Risk in VHH and BsAb Discovery with Early Immunogenicity Assessment

reduce-risk-in-vhh-and-bsab-discovery-with-early-immunogenicity-assessment-banner-1

Accelerating VHH and bispecific antibody development is no longer just about speed, it’s about progressing the right candidates with confidence. Early insights into safety, immunogenicity, and developability are critical to reducing costly downstream risks and delays.

In this webinar, ProBio will showcase an integrated discovery strategy that combines single B-cell–based antibody discovery with advanced immunogenicity assessment. This approach enables rapid identification of high-quality candidates while providing early-stage insights to support smarter decision-making.

Time

Topic

14:00-14:50

A single B cell-based novel approach to accelerate the discovery of VHH and bispecific antibody

Dr. Derek Chen, Sr. Director, Antibody Drug Discovery Dept., ProBio

Brief overview of current discovery strategy

Introduction of a novel single B cell based discovery approach

Case study with comparison between single B cell vs. phage display

14:40-15:20

De-risk of pre-clinical candidate by in silico and in vitro immunogenicity assessment

Dr. Derek Chen, Sr. Director, Antibody Drug Discovery Dept., ProBio

Applications of antibody fragments in LNP-based targeted delivery